

**"Global Licensing Agreement for Investigational HIV Compound (OBP-601)
Wins 2011 Deals of Distinction™ Award"**

Tokyo, Japan, October 20, 2011: Oncolys BioPharma Inc., Bristol-Myers Squibb Company (NYSE:BMJ) and Yale University have received a 2011 Deals of Distinction™ Award from the Licensing Executives Society (U.S.A. and Canada) in recognition of an agreement for the development of an investigational HIV compound. The compound is now known as BMS-986001/OBP-601, a once-a-day, orally available nucleoside reverse transcriptase inhibitor (NRTI) in Phase II development. The transaction was selected as winner of the Industry-University-Government Interface (IUGI) category of the Deals of Distinction™, which annually honor outstanding licensing and intellectual property-related agreements.

Early preclinical studies suggested that the compound could have an improved safety profile over previous generations of NRTIs. Oncolys licensed the compound from Yale in 2006 and developed it from pre-clinical to Phase II. In 2010, the Yale-Oncolys license was amended to help pave the way for a sub-license agreement that would enable the continued development of the compound by Bristol-Myers Squibb. The agreement is the largest sub-license to date by a Japanese biotechnology company.

"It is a great honor for Oncolys, the first Japanese biotech company, to receive such a prestigious Deals of Distinction™ Award. This award is a recognition of hard work and team effort from all members and parties involved in this transaction, I highly appreciate everyone's contribution. I have high hopes to see the compound as a new product treating and helping HIV patients worldwide." said Yasuo Urata, M.Sc., President and CEO of Oncolys BioPharma.

"This agreement was the culmination of an intricate dance between the three parties over various agreements. The negotiations required crossing time zones, as well as cultural, and language boundaries. The transaction illustrates the integral relationship between academia, biotech, and pharma. The coordination of their respective strengths exemplifies what the IUGI Sector is really about." said IUGI Sector Chair Cheryl Cejka.

"The relationships show how the intellectual capital discovered in academia, matured in biotech, and transitioned to pharma can be translated into potential treatments for millions of people by leveraging the strengths of each institution," said David Lewin, Senior Associate Director of Licensing, Yale Office of Cooperative Research.

"Collaborations between the biopharmaceutical industry and academia are vital to accelerating the discovery and development of potential new therapies. To develop and complete a successful transaction in this arena requires bringing together a large number of different elements of thinking, planning, people and organizations. As part of Bristol-Myers Squibb's String of Pearls strategy, we are developing the capabilities to knit together these important constituencies. It is this ability which will make us successful in this important arena of innovation." said Jeremy Levin, D.Phil, MB BChir., senior vice president, Strategy, Alliances and Transactions, Bristol-Myers Squibb.